Sandoz, CH1243598427

Sandoz stock target raised as AlphaValue keeps Reduce rating

Published on 11/19/2026 at 11:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sandoz stock gets a higher target from AlphaValue/Baader while the broker keeps its Reduce rating. Biosimilars remain central to the outlook.

Analyst raises target, keeps caution

  • AlphaValue/Baader lifted its Sandoz price target while retaining a Reduce rating.
  • The broker views biosimilars as the company's main long-term growth driver.
  • The revised target reflects stronger earnings assumptions but also a demanding valuation backdrop.
Sandoz, CH1243598427, Illustration mit AI erstellt.

On November 17, AlphaValue/Baader Europe raised its price target for Sandoz while retaining a Reduce rating, according to Finimize. The broker set the target at 89.9 Swiss francs after Sandoz upgraded its 2026 guidance.

Higher target, unchanged rating

The combination of a higher target and an unchanged negative rating signals a more constructive earnings view without a corresponding change in the broker's valuation stance. Finimize said AlphaValue/Baader also lifted its projected EBITDA growth rate to 6% from 5.5%.

The broker continues to identify biosimilars as the principal structural opportunity. These lower-cost versions of biologic medicines can gain share as branded products lose exclusivity, while their economics may support stronger margins than traditional generics. Sandoz has highlighted biosimilars as a core part of its growth strategy.

Valuation remains the constraint

AlphaValue/Baader's caution rests on the share-price rerating already achieved. Finimize reported that Sandoz had gained roughly 260% since its October 2023 listing, leaving less room for further upside unless operating performance continues to exceed elevated expectations.

For investors, the message is mixed. Improved assumptions for long-term profitability support a higher target, but the Reduce rating indicates that the broker does not see the revised outlook as sufficient to justify a more positive view at the current valuation. Future results, guidance and execution in the biosimilar portfolio remain important catalysts.

Sandoz stock traded at 88.45 euros on Lang & Schwarz at 11:34 CET on Thursday, November 19.

Sandoz stock facts

  • Company: Sandoz Group AG
  • ISIN: CH1243598427
  • Ticker: SDZ.SW
  • Lang & Schwarz price: 88.45 euros at 11:34 CET on November 19, 2026

The SMI is the relevant Swiss-market reference for Sandoz stock.

More news and analyses on Sandoz stock

Disclaimer...
en | CH1243598427 | SANDOZ | boerse | 70535316 | bgmi